

ProBioGen successfully completes development project by delivering recombinant Solulin to PAION for pre-clinical testing

Berlin, Aachen (Germany), 1 September 2005 - The cell line specialist ProBioGen AG and the Aachen based PAION Deutschland GmbH announced today the successful completion of a joint development project. After establishing the production process, Berlin based ProBioGen has delivered Solulin for final pre-clinical testing, thereby supporting PAION in the preparation for the first clinical Phase I study of the anticoagulant Solulin. ProBioGen will further be responsible for the manufacturing of GMP material for this study, which is anticipated to start at the end of 2005.

Solulin is a recombinant, soluble version of the human membrane protein thrombomodulin. It acts as a natural modulator of coagulation. The drug is currently being developed for the treatment of thrombotic diseases where the present anticoagulants are ineffective or are perceived to have an unsatisfactory safety profile.

ProBioGen and PAION have already been collaborating closely for several years. *"We are very glad to assist PAION with another important step in the production of the active drug substance."* said Michael Schlenk, CEO of ProBioGen. *"We've known each other for several years as true and valued partners. Collaborating also during turbulent biotech years, our relationship became even closer."* Within the scope of the Solulin manufacturing process, ProBioGen has already developed the production cell line for PAION.

"We are convinced about the quality and competence of ProBioGen and we are looking forward to our collaboration in the upcoming Phase I" commented Alexander Vos, Managing Director of PAION Deutschland GmbH and COO of PAION AG, on the completion of the development project.

About ProBioGen AG

ProBioGen is a German biotechnology company founded 1994 as a spin-off from the university hospital Charité in Berlin. ProBioGen offers services in the research and production for pharmaceutical and biotechnology companies at its certified cGMP (Good Manufacturing Practice), multi-purpose production facilities. The range of products and services includes the development of highly productive cell-lines, the production of glycoproteins for R&D and clinical testing, as well as the production of viral vectors and antibodies for in vitro diagnostics. The company is specialised in mammalian cells and combines the know-how of molecular biology scientists with the expertise in cell culture technology and process engineering. ProBioGen thus accompanies its clients from the early development of lead candidates up to late phase clinical development

About PAION

PAION Deutschland GmbH, a wholly-owned subsidiary of PAION AG, is a biopharmaceutical company based in Aachen, Germany. The company aims to become a leader in developing and commercialising innovative drugs for the treatment of stroke and other thrombotic diseases for which there is a substantial unmet medical need. Currently, PAION's activities are focused on the development of the three drugs Desmoteplase, Enecadin, and Solulin. Since 11 February 2005, PAION AG is listed at the Frankfurt Stock Exchange (Prime Standard Official Market, Stock Symbol PA8, ISIN DE000A0B65S3). During the first half-year of 2005, PAION employed on average 59 people.

Contact ProBioGen AG

Dirk Halemba
Goethestraße 54
13068 Berlin
Tel. +49 (30) 92400613
Fax +49 (30) 92400619
e-mail dirk.halemba@probiogen.de
www.probiogen.de

Contact PAION

Dr. Peer Nils Schröder
Martinstraße 10-12
52062 Aachen
Tel.: +49 (241) 4453-152
Fax: +49-(241) 4453-523
e-mail: pn.schroeder@paion.de
www.paion.de